Esperion Therapeutics (ESPR) EPS (Weighted Average and Diluted): 2019-2025
Historic EPS (Weighted Average and Diluted) for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -$0.16.
- Esperion Therapeutics' EPS (Weighted Average and Diluted) fell 6.67% to -$0.16 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.54, marking a year-over-year increase of 15.62%. This contributed to the annual value of -$0.28 for FY2024, which is 86.21% up from last year.
- Per Esperion Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.16 for Q3 2025, which was down 166.67% from -$0.06 recorded in Q2 2025.
- In the past 5 years, Esperion Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $0.34 in Q1 2024 and a low of -$3.50 during Q1 2021.
- In the last 3 years, Esperion Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.21 in 2025 and averaged -$0.25.
- In the last 5 years, Esperion Therapeutics' EPS (Weighted Average and Diluted) soared by 143.04% in 2024 and then plummeted by 161.76% in 2025.
- Esperion Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$1.53 in 2021, then surged by 51.63% to -$0.74 in 2022, then spiked by 32.43% to -$0.50 in 2023, then spiked by 78.00% to -$0.11 in 2024, then declined by 6.67% to -$0.16 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.16 in Q3 2025, compared to -$0.06 in Q2 2025 and -$0.21 in Q1 2025.